These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21239810)

  • 1. Relapsed multiple myeloma.
    Lonial S
    Hematology Am Soc Hematol Educ Program; 2010; 2010():303-9. PubMed ID: 21239810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed/refractory multiple myeloma.
    Kastritis E; Palumbo A; Dimopoulos MA
    Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition: novel therapy for multiple myeloma.
    Kaufman JL; Lonial S
    Onkologie; 2006 Apr; 29(4):162-8. PubMed ID: 16601373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel generation of agents with proven clinical activity in multiple myeloma.
    Mateos MV; Ocio EM; San Miguel JF
    Semin Oncol; 2013 Oct; 40(5):618-33. PubMed ID: 24135407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel treatment approaches for patients with multiple myeloma.
    Sinha R; Kaufman JL; Lonial S
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):281-8. PubMed ID: 16507205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment.
    Shank BR; Brown VT; Schwartz RN
    J Oncol Pharm Pract; 2015 Feb; 21(1):36-51. PubMed ID: 24395544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed and refractory multiple myeloma: new therapeutic strategies.
    Gentili S; Lonial S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of bortezomib in the treatment of multiple myeloma].
    Gotoh A; Ohyashiki K
    Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for relapsed myeloma.
    Stewart AK
    Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
    Richardson PG; Mark TM; Lacy MQ
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.